Lorenzo Leggio, a physician-scientist at the National Institutes of Health who wasnt involved in this study
After an online visit, a licensed provider determines whether the gentle approach fits and sets your plan
If a missed dose occurs, one should refer to their healthcare providers instructions, as timing can be critical
Limitations of Use: Compounded semaglutide should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist The safety and efficacy of coadministration with other products for weight loss have not been established Compounded semaglutide has not been studied in patients with a history of pancreatitis Note: Compounded medications are not FDA approved and do not have indications for treatment as an FDA approved medication would
Background Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists
The SUSTAIN 6 trial showed that subcutaneous semaglutide reduced major adverse cardiovascular events by 26% in patients with type 2 diabetes and established cardiovascular disease (hazard ratio 0.74, 95% CI 0.58-0.95)
